Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an openlabel randomised comparison  

Oleh:

Ratcliff, A. ; Siswantoro, H. ; Kenangalem, E ; Maristela, R. ; Laihad, R.M. Wuwung F. ; Ebsworth, E P ; Anstey, N M ; Tjitra, Freddy ; Price, R.N.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Lancet (keterangan: ada di Proquest) vol. 369 no. 9563 (Mar. 2007), page 757.

Ketersediaan

Perpustakaan FK Nomor Panggil: L01.K.2007.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background The burden of Plasmodium vivax infections has been underappreciated, especially in southeast Asia L, where chloroquine resistant strains have emerged. Our aim was to compare the safety and efficacy of P dihydroartemisinin-piperaquine with that of artemether-Iumefantrine in patients with uncomplicated malaria F, caused by multidrug-resistant P falciparum and P vivax. ~ Methods 774 patients in southern Papua, Indonesia, with slide-confirmed malaria were randomly assigned to receive ~' either artemether-lumefantrine or dihydroartemisinin-piperaquine and followed up for at least 42 days. The primary 51endpoint was the overall cumulative risk of parasitological failure at day 42 with a modified intention-to-treat analysis. This trial is registered with ClinicaITrials.gov, trial number 00157833. Findings Of the 754 evaluable patients enrolled, 466 had infections with P falciparum, 175 with P vivax, and 113 with a H mixture of both species. The overall risk of failure at day 42 was 43% (95% CI 38-48) for artemether.lumefantrine and 19% (14-23) for dihydroartemisinin-piperaquine (hazard ratio=3. 0, 95% CI 2.2-4.1, p

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali